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Abstract: The development of monoclonal antibodies has dramatically changed the outcome of patients
with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy. However, despite
the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured
with single-agent therapies. In this context, radioimmunotherapy, the administration of radionuclides
conjugated to monoclonal antibodies, is aimed to augment the single-agent efficacy of immunotherapy in
order to deliver targeted radiation to tumors, particularly CD20+ B-cell lymphomas. Based on evidence
from several trials in NHL, the radiolabeled antibodies 90Y-ibritumomab tiuxetan (Zevalin, Spectrum
Pharmaceuticals) and 131I-tositumomab (Bexxar, GlaxoSmithKline) received FDA approval in 2002 and
2003, respectively. However, none of the two radioimmunotherapeutic agents has been broadly applied
in clinical practice. The main reason for the under-utilization of radioimmunotherapy includes economic
and logistic considerations. However, concerns about potential side effects have also been raised.
Driven by these developments, we performed retrospective analysis of adverse events reporting Zevalin
or Bexxar, extracted from the FDA’s Adverse Event Reporting System (FAERS) and the World Health
Organization’s VigiBase repository. Our results indicate that the two radioimmunotherapeutic agents
have both related and distinct side effect profiles and confirm their known toxicological considerations.
Our work also suggests that computational analysis of real-world post-marketing data can provide
informative clinical insights. While more prospective studies are necessary to fully characterize the
efficacy and safety of radioimmunotherapy, we expect that it has not yet reached its full therapeutic
potential in modern hematological oncology.
Keywords: non-Hodgkin’s lymphoma; radioimmunotherapy; 90Y-ibritumomab tiuxetan (Zevalin),
131I-tositumomab (Bexxar), FDA’s Adverse Event Reporting System (FAERS), VigiBase
1. Introduction
The development and introduction of monoclonal antibodies in clinical practice have constituted
a true revolution in the management of non-Hodgkin’s lymphoma (NHL), the most frequent
hematologic malignancy. CD20, a transmembrane calcium channel protein, represents the most
common target antigen for monoclonal antibody therapy, since it is expressed at high density on most
B-cell lymphomas [1]. Rituximab was the first monoclonal antibody approved by the U.S. Food and
Drug Administration (FDA) in 1997, for the treatment of relapsed or refractory, low-grade (indolent) or
follicular, CD20+ NHL. Rituximab is directed against the CD20 antigen and exerts its antitumor effect
by activation of antibody-dependent cell-mediated cytotoxicity through complement activation and
induction of apoptosis [2]. However, despite the satisfying results of monoclonal antibody treatment,
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only few patients are permanently cured with single-agent therapy: fewer than half of follicular NHL
patients respond to Rituximab with median response duration of about a year, since they may not
respond or may develop resistance to antibody therapy [3,4].
Radioimmunotherapy represents an attempt to augment the single-agent efficacy of this therapeutic
approach in NHL by conjugating therapeutic radionuclides to the monoclonal antibodies in order to
deliver radiation to these tumors [5], which are known to be more radiosensitive than solid tumors
and other types of cancer [6–9]. The mechanism of action of radioimmunotherapy on tumor cells
involves a combination of the antibody-stimulated cytolysis and induction of apoptosis, with the
ionizing radiation emitted from the radioisotope, which generates free radicals leading to cellular
damage. Moreover, due to the “crossfire” radiation effect, adjacent tumor cells that do not bind the
antibody may still be killed [5].
The radiolabeled antibodies 90Y-ibritumomab tiuxetan (Zevalin; Spectrum Pharmaceuticals) and
131I-tositumomab (Bexxar; GlaxoSmithKline) received FDA approval in 2002 and 2003, respectively,
based on impressive results from several trials [10–13]. Zevalin was initially approved for treatment
of patients with relapsed or refractory low-grade, follicular B-cell NHL, including patients with
Rituximab-refractory follicular NHL. In 2014, it received expanded approval to include the first-line
consolidation therapy of NHL patients following initial treatment with front-line chemotherapy; this
approval was based on the results of a randomized multicenter phase III trial involving 414 patients
with newly diagnosed advanced follicular lymphoma [14]. Bexxar was also approved for the treatment
of relapsed, refractory, and transformed indolent lymphomas.
Despite the proven efficacy of radioimmunotherapy, not only in the relapsed/refractory setting
but also in newly diagnosed patients with high response rates and durable remissions [14–18], this
treatment modality has failed to be widely adopted by the hematooncology community. As a result,
this led to commercial failure of the two products, reaching its nadir in 2014 with the discontinuation
of U.S. production of Bexxar due to decreasing sales of the agent [4,19].
Although economic and logistic considerations have played a key role in the underuse of
radioimmunotherapy, concerns about potential side effects related to radiation exposure, particularly
the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), have also
been raised [4]. Driven by these developments, we sought to characterize the safety profile of this
treatment modality based on accessible sources of real-world data. For this reason, adverse events
(AEs) of patients receiving Zevalin or Bexxar reported in the FDA’s Adverse Event Reporting System
(FAERS) and in the World Health Organization’s (WHO) global Individual Case Safety Report (ICSR)
database (VigiBase) were extracted and analyzed.
2. Materials and Methods
We profiled Bexxar and Zevalin AEs by extracting data from the FAERS (incl. 2017Q2) and
VigiBase (incl. 2018Q2) repositories.
2.1. Data Integration
The public FAERS dataset contained 7.9 million cases and held records regarding the patients’
treatments (medications), the indications of those treatments (disease or condition), and the observed
reactions and outcomes (e.g., “death” or “hospitalization”) reported in these AEs. To compensate for
ambiguities introduced by the non-standardized use of drug names [20], FAERS free-text medication
descriptions were consolidated via a stepwise process that matched each name to standardized
dictionaries [21]. Indications and reactions, coded by FAERS in terms from the Medical Dictionary for
Regulatory Activities (MedDRA), were analyzed at the Preferred Term (PT) level (i.e., MedDRA Level
4 descriptions). Similarly, we processed the VigiBase dataset that held 17095324 AE cases.
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2.2. Statistical Analysis
From each dataset (FAERS, VigiBase), we extracted two separate AE cohorts for Bexxar and
Zevalin, respectively defined as follows:
• FAERS Bexxar cohort: 290 AEs (FAERS cases annotated with the ‘Tositumomab’ drug record).
• FAERS Zevalin cohort: 1196 AEs (FAERS cases annotated with the ‘Ibritumomab’ drug record).
• VigiBase Bexxar cohort: 307 AEs (VigiBase cases with product (drug) names mentioning ‘Bexxar’
or ‘Tositumomab’).
• VigiBase Zevalin cohort: 1125 AEs (VigiBase cases with product (drug) names mentioning ‘Zevalin’
or ‘Ibritumomab’).
For the statistical characterization of the cohorts, we employed the proportional reporting ratio
(PRR) metric, an established measure of disproportionality in pharmacovigilance for the evaluation of
signals generated from spontaneous reporting data [22]. PRRs were computed using the approach
described by van Puijenbroek et al. [23].
Each cohort was characterized with respect to the occurrence of drugs, outcomes, indications
and reactions reported in the respective AEs. We also considered relevant statistical significance
reflected by Fisher’s exact test p-values (two-tailed). In this study, we considered statistical significance
indicated by a p-value of 5% or lower (i.e., when p-value < 0.05). To structure the statistical analysis,
each cohort’s AEs were compared against the remaining respective dataset’s AEs (whether FAERS or
VigiBase) during the calculation of PRR and Fisher’s exact test scores.
Results for each cohort are summarized in the Supplementary Material file: results per cohort list
the observed case counts (i.e., number of AEs that a certain occurrence was observed in each cohort),
percentage of occurrence within each cohort’s cases, and the respective PRR disproportionality scores
and Fisher’s test p-values. The Supplementary Material file contains all observations for consideration
by the community, irrespective of their PRR or Fisher’s exact test signals.
3. Results
Our dataset consisted of AEs extracted from FAERS and VigiBase that reported use of Bexxar
or Zevalin. As expected, ‘non-Hodgkin’s lymphoma’, as well as other PTs describing—more or less
specific—forms of lymphoma were reported as treatment indication in the vast majority of the reported
cases in all cohorts (see Supplementary Material file). With the exception of three patient cases,
where both drugs have been co-reported—most likely in succession one after the other—Zevalin and
Bexxar were not reported in the same AEs. The most frequent medication reported with Zevalin was
Rituximab, mentioned in 70% of its FAERS AEs. In comparison, Rituximab was mentioned only in 15%
of Bexxar’s AEs in FAERS.
The identified AE trends were likely reflective of clinical usage trends (Figure 1), including the
decreasing course of their use during the last years. Despite the certain collection lag existing in the
capture of respective AEs, the historical timeline portrays both the initial increase that followed the
agents’ FDA approvals as well as their decline, particularly for Bexxar. Zevalin’s temporary increase
after 2014 probably represents its indication expansion to include the first-line consolidation therapy of
NHL patients following initial treatment with front-line chemotherapy.
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Figure 1. Timeline of AEs reporting Zevalin and Bexxar in the FDA’s Adverse Event Reporting 
System (FAERS). Overall, there are more AEs identified for Zevalin in FAERS, likely indicating 
broader usage adoption than for Bexxar. Fourteen cases reporting Bexxar prior to 2001 are not 
displayed. Also, the distribution of AEs over time does not include incompletely reported cases for 
which no date was specifically registered. Last, AEs dated prior to a drug’s approval may reflect 
reports from preapproval studies and clinical trials. The reduction of AE numbers for 2017 is 
explained by the fact that the full dataset for that year was not yet released by FAERS at the time this 
analysis took place. Note that a certain time delay between the disclosure of reports to FAERS and 
the date of an event or the use of an agent is reasonable to be expected. 
Overall, FAERS and VigiBase contained similar adverse reaction profiles for each 
radioimmunotherapeutic agent. Table 1 juxtaposes key patient outcomes reported in the respective 
radioimmunotherapeutic agent cohorts. 
Table 1. Selected outcomes reported in the two datasets; all adverse events (AE) cases considered per 
cohort. Note that the outcomes associated to a single event may be more than one. 
Outcome % Zevalin AEs % Bexxar AEs FAERS VigiBase FAERS VigiBase 
Death 33.4 22.8 22.1 24.1 
Hospitalization 41.5 22.1 31.0 20.5 
Life threatening 7.4 3.9 7.9 5.2 
Other 46.3 31.8 36.6 23.1 
3.1. Adverse Event Profiling 
Next, side effect profiles for those cohorts were extracted: Tables 2–5 summarize up to the thirty 
most frequently reported reactions in each cohort, described in MedDRA PTs (i.e., level 4 terms). The 
following PTs did not reflect drug-induced effects and were therefore excluded from these tables, 
whenever mentioned: ‘Disease progression’, ‘Malignant neoplasm progression’, ‘Drug ineffective’, 
‘Stem cell transplant’, ‘Non-Hodgkin’s lymphoma’, ‘Death’. 
3.1.1. Zevalin Reactions 
In both datasets (FAERS, VigiBase), cytopenias were the most commonly reported reactions 
with Zevalin (Tables 2 and 3). More specifically, ‘thrombocytopenia’, and ‘neutropenia’ were the 
most frequent reaction PTs, followed by ‘leukopenia’ and ‘pancytopenia’. Among the most 
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Figure 1. Timeline of AEs reporting Zevalin and Bexxar in the FDA’s Adverse Event Reporting System
(FAERS). Overall, there are more AEs identified for Zevalin in FAERS, likely indicating broader usage
adoption than for Bexxar. Fourteen cases reporting Bexxar prior to 2001 are not displayed. Also,
the distribution of AEs over time does not include incompletely reported cases for which no date was
specifically registered. Last, AEs dated prior to a drug’s approval may reflect reports from preapproval
studies and clinical trials. The reduction of AE numbers for 2017 is explained by the fact that the full
dataset for that year was not yet released by FAERS at the time this analysis took place. Note that
a certain time delay between the disclosure of reports to FAERS and the date of an event or the use of
an agent is reasonable to be expected.
Overall, FAERS and VigiBase contained similar adverse reaction profiles for each radioimmunotherapeutic
agent. Table 1 juxtaposes key patient outcomes reported in the respective radioimmunotherapeutic agent cohorts.
Table 1. Selected o tcomes reported in the two datasets; all adverse event (AE) cases considered per
cohort. Note that the outcomes associated to a single event may be more than one.
Outcome
% Zevalin AEs % Bexxar AEs
FAERS VigiBase FAERS VigiBase
Death 33.4 22.8 22.1 24.1
Hospitalization 41.5 22.1 31.0 20.5
Life threatening 7.4 3.9 7.9 5.2
O her 46.3 31.8 6 6 23 1
3.1. Adverse Event Profiling
Next, side effect profiles for those cohorts were extracted: Tables 2–5 summarize up to the thirty
most frequently reported reactions in each cohort, described in MedDRA PTs (i.e., level 4 terms).
The following PTs did not reflect drug-induced effects and were therefore excluded from these tables,
whenever mentioned: ‘Disease progression’, ‘Malignant neoplasm progression’, ‘Drug ineffective’,
‘Stem cell transplant’, ‘Non-Hodgkin’s lymphoma’, ‘Death’.
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Table 2. Most frequently reported MedDRA preferred term (PT) reactions (level 4 terms) with Zevalin
in FAERS. All observations are statistically significant, with p-value < 0.05.
Reaction (MedDRA PT) Name Number of AEs_in Cohort PRR Cohort %
Thrombocytopenia 1 151 21.4 12.6
Neutropenia 124 19.0 10.4
Sepsis 98 13.0 8.2
White blood cell count decreased 2 84 13.2 7.0
Myelodysplastic syndrome (MDS) 83 74.1 6.9
Platelet count decreased 1 80 12.0 6.7
Pyrexia 79 3.4 6.6
Pancytopenia 78 20.0 6.5
Febrile neutropenia 76 20.9 6.4
Anaemia 3 65 4.7 5.4
Bone marrow failure 63 37.3 5.3
Diarrhoea 60 1.7 5.0
Pneumonia 57 2.9 4.8
Haemoglobin decreased 3 51 6.6 4.3
Meningitis tuberculous 49 1489.1 4.1
Multi-organ failure 44 15.9 3.7
Acute myeloid leukaemia (AML) 43 42.5 3.6
Leukopenia 2 43 13.6 3.6
Neutrophil count decreased 42 19.4 3.5
Progressive multifocal leukoencephalopathy 38 64.5 3.2
Nausea 36 0.7 3.0
Cytomegalovirus infection 33 37.4 2.8
Septic shock 33 12.7 2.8
Mucosal inflammation 32 19.7 2.7
Infection 32 4.0 2.7
Renal failure 31 3.5 2.6
1 The terms ‘Thrombocytopenia’ and ‘Platelet count decreased’ refer to the same condition. 2 The terms ‘White
blood count decreased’ and ‘Leukopenia’ refer to the same condition. 3 The terms ‘Anaemia’ and ‘Haemoglobin
decreased’ refer to the same condition.
Table 3. Most frequently reported MedDRA PT reactions (level 4 terms) with Zevalin in VigiBase.
All observations are statistically significant, with p-value < 0.05.
Reaction (MedDRA PT) Name Number of AEs_in Cohort PRR Cohort %
Thrombocytopenia 1 165 20.1 14.7
Neutropenia 157 24.2 14.0
Platelet count decreased 1 117 35.2 10.4
Pancytopenia 90 37.2 8.0
Sepsis 71 20.0 6.3
White blood cell count decreased 2 71 18.4 6.3
Myelodysplastic syndrome (MDS) 69 170.1 6.1
Anaemia 3 59 6.1 5.2
Pneumonia 53 5.2 4.7
Pyrexia 51 1.4 4.5
Febrile neutropenia 50 26.2 4.4
Leukopenia 2 48 9.1 4.3
Neutrophil count decreased 42 24.1 3.7
Meningitis tuberculous 37 3877.3 3.3
Nausea 37 0.6 3.3
Fatigue 34 1.2 3.0
Diarrhoea 34 1.0 3.0
Acute myeloid leukaemia (AML) 33 93.7 2.9
Bone marrow failure 32 15.1 2.8
Pain 29 1.2 2.6
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Table 3. Cont.
Reaction (MedDRA PT) Name Number of AEs_in Cohort PRR Cohort %
Progressive multifocal leukoencephalopathy 27 131.5 2.4
Haemoglobin decreased 3 25 7.0 2.2
Dyspnoea 24 0.7 2.1
Dehydration 23 4.6 2.0
Vomiting 23 0.6 2.0
Asthenia 23 1.2 2.0
1 The terms ‘Thrombocytopenia’ and ‘Platelet count decreased’ refer to the same condition. 2 The terms ‘White
blood count decreased’ and ‘Leukopenia’ refer to the same condition. 3 The terms ‘Anaemia’ and ‘Haemoglobin
decreased’ refer to the same condition.
Table 4. Most frequently reported MedDRA PT reactions (level 4 terms) with Bexxar in FAERS.
All observations are statistically significant, with p-value < 0.05.
Reaction (MedDRA PT) Name Number of AEs_in Cohort PRR Cohort %
Myelodysplastic syndrome (MDS) 46 168.7 15.9
Pyrexia 30 5.3 10.3
Acute myeloid leukaemia (AML) 22 89.4 7.6
Fatigue 22 2.0 7.6
Dyspnoea 21 2.4 7.2
Nausea 18 1.4 6.2
Anaemia 17 5.1 5.9
Thrombocytopenia + 16 9.3 5.5
Pancytopenia 14 14.8 4.8
Hypotension 14 4.4 4.8
Febrile neutropenia 13 14.7 4.5
Neutropenia 13 8.2 4.5
Chills 13 6.7 4.5
Lymphadenopathy 12 20.4 4.1
Pneumonia 12 2.6 4.1
Vomiting 12 1.6 4.1
Dizziness 12 1.5 4.1
Infusion related reaction 11 14.9 3.8
Rash 11 1.9 3.8
Platelet count decreased + 10 6.2 3.4
Back pain 10 2.7 3.4
Arthralgia 10 1.8 3.4
Asthenia 10 1.7 3.4
Pleural effusion 9 8.1 3.1
Cardiac failure congestive 9 4.2 3.1
Decreased appetite 9 2.5 3.1
Weight decreased 9 2.1 3.1
+ The terms ‘Thrombocytopenia’ and ‘Platelet count decreased’ refer to the same condition.
Table 5. Most frequently reported MedDRA PT reactions (level 4 terms) with Bexxar in VigiBase.
All observations are statistically significant, with p-value < 0.05.
Reaction (MedDRA PT) Name Number of AEs_in Cohort PRR Cohort %
Myelodysplastic syndrome (MDS) 43 386.9 14.0
Acute myeloid leukaemia (AML) 27 280.5 8.8
Pyrexia 27 2.7 8.8
Fatigue 22 2.8 7.2
Dyspnoea 20 2.3 6.5
Thrombocytopenia + 18 8.0 5.9
Nausea 17 1.0 5.5
Pharmaceuticals 2019, 12, 141 7 of 13
Table 5. Cont.
Reaction (MedDRA PT) Name Number of AEs_in Cohort PRR Cohort %
Febrile neutropenia 15 28.7 4.9
Pancytopenia 15 22.7 4.9
Anaemia 15 5.7 4.9
Neutropenia 13 7.3 4.2
Pneumonia 13 4.7 4.2
Hypotension 13 4.0 4.2
Chills 13 3.7 4.2
Lymphadenopathy 12 16.6 3.9
Infusion related reaction 11 24.8 3.6
Infection 11 8.3 3.6
Back pain 11 4.1 3.6
Rash 11 0.8 3.6
Platelet count decreased + 10 11.0 3.3
Pain in extremity 10 2.8 3.3
Arthralgia 10 2.2 3.3
Asthenia 10 1.9 3.3
Vomiting 10 0.9 3.3
White blood cell count decreased 9 8.6 2.9
Cardiac failure congestive 9 7.9 2.9
Weight decreased 9 3.7 2.9
+ The terms ‘Thrombocytopenia’ and ‘Platelet count decreased’ refer to the same condition.
3.1.1. Zevalin Reactions
In both datasets (FAERS, VigiBase), cytopenias were the most commonly reported reactions with
Zevalin (Tables 2 and 3). More specifically, ‘thrombocytopenia’, and ‘neutropenia’ were the most
frequent reaction PTs, followed by ‘leukopenia’ and ‘pancytopenia’. Among the most frequently
reported reaction PTs there were only few infusion related terms (such as urticaria, hypotension,
angioedema, hypoxia, bronchospasm, or cardiogenic shock), with the exception of ‘dyspnea’ that was
reported in 2.1% of the VigiBase Zevalin cohort. Reaction PT ‘pyrexia’ had a somewhat increased PRR
(3.4 in FAERS, 1.4 in VigiBase) and even though it might represent an infusion related reaction, it could
also occur in the context of an infection or inflammation. ‘Sepsis’, ‘febrile neutropenia’ and a variety of
infections and inflammations (including ‘mucosal inflammation’) were also often reported with the
agent and had increased PRR scores. Interestingly, reaction PT ‘Meningitis tuberculous’ had a very
high PRR signal in both Zevalin datasets. Among the reaction PTs with high PRR signals were also
‘Myelodysplastic syndrome’ (MDS) and ‘acute myeloid leukemia’ (AML). MDS was reported in 6.9%
and 6.1% of the corresponding FAERS and VigiBase cohorts, while AML was reported in 3.6% and
2.9% of the respective FAERS and VigiBase Zevalin cohorts.
3.1.2. Bexxar Reactions
Bexxar cohorts were smaller in size as compared to the Zevalin ones. The most frequently reported
PTs with Bexxar were MDS (15.9% in FAERS, 14.0% in VigiBase), ‘pyrexia’ (10.3% in FAERS, 8.8% in
VigiBase), AML (7.6% in FAERS, 8.8% in VigiBase), ‘fatigue’ (7.6% in FAERS, 7.2% in VigiBase) and
‘dyspnea’ (7.2% in FAERS, 6.5% in VigiBase). As in the case of Zevalin, cytopenias were also frequently
reported with Bexxar in both datasets. In contrast, allergic/infusion reaction PTs such as ‘dyspnea’,
‘hypotension’, ‘chills’ and ‘vomiting’ were recorded in a higher proportion of the respective cohorts for
Bexxar (Tables 4 and 5).
4. Discussion
Despite the promising results from clinical trials providing evidence regarding the efficacy
and safety of radioimmunotherapy, neither of the two approved radioimmunotherapeutic agents
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found broad application in clinical practice. Bexxar exited the US market in 2014 after low sales,
whereas nowadays Zevalin is not often used in the treatment of NHL. Although economic and logistic
considerations played an important role in the underutilization of these agents [24], one other key
concern regarding radioimmunotherapy is its toxicity profile and, more specifically, bone marrow
damage and unexpected late side effects—particularly, the development of MDS and AML [3,25].
In this work, we examined such considerations by analyzing real world post-marketing AE data
extracted from FAERS and VigiBase. Our results provide additional insights into the safety profile
of radioimmunotherapy. Table 6 summarizes the most frequently reported reactions for Zevalin and
Bexxar in both datasets by organizing them in groups of main classes.
Table 6. Most frequently reported MedDRA PT reactions (level 4 terms) with Zevalin and Bexxar in
both datasets categorized in groups.
Zevalin Bexxar
Blood/Cytopenias
Thrombocytopenia
Neutropenia
Leukopenia
Pancytopenia
Anemia
Bone marrow failure
Anemia
Thrombocytopenia
Pancytopenia
Neutropenia
Infections/Inflammations
Sepsis
Pyrexia +
Febrile neutropenia
Pneumonia
Meningitis tuberculous
Cytomegalovirus infection
Septic schock
Mucosal inflammation
Pyrexia +
Febrile neutropenia
Chills
Pneumonia
Secondary malignancies
Myelodysplastic syndrome (MDS) Myelodysplastic syndrome (MDS)
Acute myeloid leukaemia (AML) Acute myeloid leukaemia (AML)
Gastrointestinal
Diarrhoea
Nausea Nausea
Other
Multi-organ failure
Progressive multifocal
leukoencephalopathy
Renal failure
Fatigue
Pain
Asthenia
Dehydration
Fatigue
Dyspnoea
Hypotension
Chills
Lymphadenopathy
Dizziness
Infusion related reaction
Rash
Back pain
Arthralgia
Asthenia
Pleural effusion
Cardiac failure congestive
Decreased appetite
Weight decreased
+ The term ‘pyrexia’ could be an infusion reaction but also an infection sign.
The analysis of the Zevalin AE cohorts confirmed its known toxicological profile [26–28]. The high
occurrence of cytopenias may be attributed to bone marrow suppression induced by the agent, while
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infections, inflammations and related side effects were also often reported, with sepsis, pyrexia and
febrile neutropenia being the most frequent ones. Despite its consideration as one of the most common
Zevalin AEs, ‘nasopharyngitis’ was only occasionally reported as such (mentioned only in two AE cases
of the FAERS Zevalin cohort, as reaction) [26]. Interestingly, ‘nausea’, ‘dyspnea’ and ‘vomiting’ had
lower PRR scores (<1), despite their reported frequency in the FAERS and/or VigiBase Zevalin cohorts
(>2%). In contrast, the data suggest ‘tuberculous meningitis’ as a rather specific reaction PT related to
the Zevalin cohorts, containing a significant 17.5% and 14.8% of the term’s total mentioning in FAERS
and VigiBase, respectively. However, we could not confirm this observation in the literature, nor assess
further whether this occurrence could be attributed to some sort of reporting bias or co-medication
effects. Without access to detailed clinical data or the original AE narratives, we observed that almost
all of Zevalin’s FAERS tuberculous meningitis AEs were in patients being pre- or co-medicated with
chemotherapeutic agents such as Vincristine, Doxorubicin and Etoposide, as well as Prednisone.
Secondary malignancies, namely MDS and AML, were also reported with Zevalin. More specifically,
MDS was reported with Zevalin in FAERS with an occurrence of 6.9% and AML with 3.6%, and
respectively in 6.1% and 2.9% of the VigiBase Zevalin cohort. This is in agreement with the cumulative
incidence of MDL/AML in 5.2% of patients with relapsed or refractory NHL enrolled in Zevalin clinical
studies [26]. However, the majority of Zevalin patients first receive Rituximab treatment and it is therefore
difficult to determine which of these agents has primarily contributed to the occurrence of MDS and
AML in the examined AEs, especially when Rituximab itself is also considered as a potential risk factor
for the development of these secondary malignancies [29–32]. One other observation that supports this
concern is the reporting of ‘progressive multifocal leukoencephalopathy’ and ‘cytomegalovirus infection’,
which are identified risks of Rituximab therapy [29]. Finally, ‘mucosal inflammation’—a significant
consideration in terms of Zevalin treatment—was reported in 2.7% of the FAERS Zevalin cohort, whereas
only few serious infusion related reactions, which are considered potentially severe during therapy with
Zevalin and sometimes even fatal [26], were reported.
The analysis of the smaller Bexxar cohorts revealed a somewhat different toxicological profile,
in comparison to Zevalin. This is in part expected, given that ibritumomab tiuxetan is radiolabeled
with 90Y while tositumomab is radiolabeled with 131I—even though both radionuclides are beta
emitters, they possess different characteristics regarding physical half-life, maximum beta energy,
penetration length of their beta emissions, as well as emission of gamma radiation. Such physical
differences of the radionuclides directly influence both the biodistribution and the dosimetry of the
radioimmunoconjugate applied, which in turn affect their toxicity. To determine radiation exposure
to various organs and to confirm tumor targeting, dosimetry is incorporated into the design of
radioimmunotherapy regimens [33]. However, dosimetry is not required with Zevalin, since the first
dosimetry analyses of the agent in several clinical trials with relapsed or refractory NHL showed that
radiation absorbed doses were within safety limits and did not correlate with toxicity [34,35]. While
the administered activity of Zevalin is mainly determined by patient weight and baseline platelet
count, dosimetry before radioimmunotherapy with the 131I-labeled Bexxar is mandatory to determine
the appropriate delivered activity [36].
The first difference between the two agents related to the occurrence of secondary malignancies
that were reported in a higher proportion among Bexxar’s cohorts: MDS was reported in 15.9% and
AML in 7.6% of the respective FAERS cohort and, accordingly, in 14.0% and 8.8% of the VigiBase cohort.
These findings are in line with the cumulative incidence of MDS/secondary leukemia observed in 10%
of patients enrolled in Bexxar clinical trials with a median follow-up of 39 months [37]. Infusion/allergic
reactions were also reported in higher proportions among Bexxar AEs as compared to Zevalin, with
‘dyspnea’, ‘hypotension’, ‘chills’, ‘vomiting’ and ‘rash’ being mentioned in more than 3% of each
cohort’s cases. However, ‘nausea’, ‘rash’ and ‘vomiting’ had lower PRR scores (≤1) in Bexxar’s VigiBase
cohort. Moreover, pyrexia, which could be either an infusion reaction or an infection sign, was in both
Bexxar datasets second only to MDS and AML.
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Interestingly, cytopenias were reported in smaller proportions of the Bexxar cohorts, when
compared to Zevalin. Similarly, this was the case also for infections, inflammations and their related
reactions, with pyrexia, febrile neutropenia and pneumonia being the most frequently reported.
Hypothyroidism, a main concern regarding Bexxar usage due to Iodine 131I, was only occasionally
reported (mentioned only in one AE case of the VigiBase Bexxar cohort, as reaction). One possible
reason for this might be the effective use by the community of thyroid-blocking medication prior to the
administration of this radioimmunotherapeutic regimen.
Overall, results from the analysis of Zevalin AEs confirmed its known toxicological profile,
consistent with findings from clinical trials as well as descriptions presented in the agent’s label.
However, among Bexxar AEs secondary malignancies ranked first, before other commonly expected
side effects such as cytopenias, infections, infusion reactions, asthenia or nausea, observed in > 25%
of treated patients in some clinical trials [37]. This may be explained by the fact that FAERS and
VigiBase contain reports of AEs and not all potential side effects, as documented in clinical trials
and prospective studies. Bexxar cohorts were also smaller in size compared to Zevalin, therefore
possibly not equivalently representative. One other aspect to consider is the potential bias that may
underlie radioimmunotherapy AE reporting. Such a bias may be manifested in several ways, such as
the use of terms coming from a particular terminology (medical/technical language), reporting of
AEs occurring/examined in specific circumstances, prejudice of reporters (e.g., affected by media or
peer commentaries), as well as failure to mention some reactions simply because they are known or
not severe. Reporting bias may, for example, explain over- or under-representation of certain effects,
such as in the cases of nasopharyngitis, or the reporting of infusion reactions among Zevalin AEs.
Furthermore, causal etiologies underlying the observed events could not be clearly determined as
both Zevalin and Bexxar were frequently mentioned with agents known to potentially increase the
risk or severity of adverse effects when combined together (such as Rituximab, Cyclophosphamide,
Prednisone, Vincristine, Doxorubicin, Fludarabine and Etoposide).
Due to practical limitations, the present study could not consider specific severity grading of
reported reactions, information regarding treatment duration or previous therapies, de-/re-challenge
information, patient/event history and demographics, as well as data regarding dosage of the applied
radioactive pharmaceuticals. Moreover, reported frequencies do not represent occurrence in the general
treated population, but in patients who manifested AEs under therapy and their incidence was reported.
As with other studies of AEs e.g., [38,39], our results should therefore not be interpreted as calculated
incidences of side effects in the general NHL patient population receiving these radioimmunotherapeutic
agents. This is not the intended use of data coming from spontaneous AE repositories since they contain
only AEs and are therefore biased without proper normalization considering reference/control data.
Nonetheless, AE analytics provide certain advantages and systematic insights in the toxicological
profiling of therapeutic agents. Not only do they serve as an augmented data stream capturing
real-world scenarios regarding therapeutic uses and conditions not studied in clinical-trials, but they
also include information for many more patients [21,40]. When available, AE analytics can further
benefit from the examination of additional data regarding laboratory and clinical parameters.
For example, molecular dissection of AEs has been shown to effectively improve clinical insights,
as well as inform about potential drug-drug interactions or other mechanisms underlying observed
outcome phenotypes e.g., [41,42]. Such information could be important within the broader context of
immunotherapy, potentially providing useful markers for the use of these agents in NHL patients.
Indeed, results from recent NHL trial studies provide updated evidence regarding the efficacy and
safety of radioimmunotherapy, possibly inspiring reconsideration of Zevalin and Bexxar’s clinical
utility in modern hematological oncology [43–45].
5. Conclusions
We investigated the toxicological profile of radioimmunotherapeutic agents on NHL, by performing
a retrospective analysis of AE cases of patients receiving Zevalin or Bexxar, reported in FDA’s FAERS
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and WHO’s VigiBase repositories. Overall, our results recapitulate known side effects observed with
radioimmunotherapy and confirm cytopenias, infections, inflammations, infusion reactions, as well as
MDS and AML as some of the main patient safety concerns. The present work also suggests that
computational analysis of real-world patient outcome data can provide informative insights in the
field of the toxicological profiling of therapeutic agents. While such analytics can certainly benefit
from the consideration of additional clinical information, we also call for more studies required to
characterize the efficacy and safety of radioimmunotherapy in NHL.
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